[1]庞乃栋,张楠,郭敏,等.生物标志物对心房颤动射频消融术后复发的预测作用[J].国际心血管病杂志,2022,05:261-263.
点击复制
生物标志物对心房颤动射频消融术后复发的预测作用(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2022年05期
- 页码:
- 261-263
- 栏目:
- 综述
- 出版日期:
- 2022-10-01
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2022.05.002
- 文献标识码:
- -
- 摘要:
- 射频消融是心房颤动（房颤）的有效治疗措施，但房颤在术后仍存在一定的复 发率。研究发现，术前某些指标升高的房颤患者，在接受射频消融术后复发率明显较高，这些 生物标志物包括血清胆红素、半乳糖凝集素-3、低密度脂蛋白胆固醇、脑钠肽及部分炎性 因子等，其水平与术后复发独立相关，有助于预测患者预后。
- Abstract:
- -
参考文献/References
[1] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines
for the diagnosis and management of atrial fibrillation
developed in collaboration with the European Association
for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J, 2021,
42(5):373-498.
[2] Poole JE, Bahnson TD, Monahan KH, et al. Recurrence of
atrial fibrillation after catheter ablation or antiarrhythmic drug
therapy in the CABANA trial[J]. J Am Coll Cardiol, 2020,
75(25):3105-3118.
[3] Carballo D, Noble S, Carballo S, et al. Biomarkers and
arrhythmia recurrence following radiofrequency ablation of
atrial fibrillation[J]. J Int Med Res, 2018, 46(12):5183-5194.
[4] Samsky MD, Patel CB, DeWald TA, et al. Cardiohepatic
interactions in heart failure: an overview and clinical
implications[J]. J Am Coll Cardiol. 2013, 61(24):2397-2405.
[5] Chen SC, Chung FP, Chao TF, et al. A link between bilirubin
levels and atrial fibrillation recurrence after catheter
ablation[J]. J Chin Med Assoc, 2019, 82(3):175-178.
[6] Targher G, Byrne CD. Circulating markers of liver function
and cardiovascular disease risk[J]. Arterioscler Thromb Vasc
Biol, 2015, 35(11):2290-2296.
[7] Yaegashi T, Kato T , Usui S, et al. Short-term rapid atrial
pacing alters the gene expression profile of rat liver:cardiohepatic interaction in atrial fibrillation[J]. Heart Rhythm,
2016,13(12):2368-2376.
[8] Ayer A, Zarjou A, Agarwal A, et al. Heme oxygenases in
cardiovascular health and disease[J]. Physiol Rev, 2016,
96(4):1449-1508.
[9] Dzeshka MS, Lip GY, Snezhitskiy V, et al. Cardiac fibrosis
in patients with atrial fibrillation: mechanisms and clinical
implications[J]. J Am Coll Cardiol, 2015, 66(8):943-959.
[10] Dong R, Zhang M, Hu Q, et al. Galectin-3 as a novel
biomarker for disease diagnosis and a target for therapy
(Review)[J]. Int J Mol Med, 2018, 41(2):599-614.
[11] Pranata R, Yonas E, Chintya V, et al. Serum Galectin-3 level
and recurrence of atrial fibrillation post-ablation-Systematic
review and meta-analysis[J]. Indian Pacing Electrophysiol J,
2020, 20(2):64-69.
[12] Gurses KM, Yalcin MU, Kocyigit D, et al. Effects of persistent
atrial fibrillation on serum galectin-3 levels[J]. Am J Cardiol,
2015, 115(5):647-651.
[13] Kimura T, Takatsuki S, Inagawa K, et al. Serum inflammation
markers predicting successful initial catheter ablation for atrial
fibrillation[J]. Heart Lung Circ, 2014, 23(7):636-643.
[14] Jiang H, Wang W, Wang C, et al. Association of pre-ablation
level of potential blood markers with atrial fibrillation
recurrence after catheter ablation: a meta-analysis[J].
Europace, 2017, 19(3):392-400.
[15] Li A, Chen Y, Wang W, et al. Association of clinical predictors
with recurrence of atrial fibrillation after catheter ablation[J].
Ann Noninvasive Electrocardiol, 2020, 25(6):e12787.
[16] Bastiaanse EM, H?ld KM, Van der Laarse A. The effect of
membrane cholesterol content on ion transport processes in
plasma membranes[J]. Cardiovasc Res, 1997, 33(2):272-283.
[17] Giannopoulos G, Vrachatis D, Kossyvakis C, et al. Effect
of postablation statin treatment on arrhythmia recurrence in
patients with paroxysmal atrial fibrillation[J]. J Cardiovasc
Pharmacol, 2018, 72(6):285-290.
[18] Thamilarasan M, Klein AL. Factors relating to left atrial
enlargement in atrial fibrillation: "chicken or the egg"
hypothesis[J]. Am Heart J, 1999, 137(3):381-383.
[19] Rationale and design of a study assessing treatment strategies
of atrial fibrillation in patients with heart failure: the Atrial
Fibrillation and Congestive Heart Failure (AF-CHF) trial[J].
Am Heart J, 2002, 144(4):597-607.
[20] Hansson M. Natriuretic peptides in relation to the cardiac
innervation and conduction system[J]. Microsc Res Tech,
2002, 58(5):378-386.
[21] 徐敏, 刘飞, 葛志翔, 等. 阵发性心房颤动患者环肺静脉射频
消融术后复发的预测因素研究[J]. 中华医学超声杂志(电子
版), 2020, 17(12):1220-1226.
[22] Guo Y, Lip GY, Apostolakis S. Inflammation in atrial
fibrillation[J]. J Am Coll Cardiol, 2012, 60(22):2263-2270.
[23] Marott SC, Nordestgaard BG, Zacho J, et al. Does elevated
C-reactive protein increase atrial fibrillation risk? A Mendelian
randomization of 47,000 individuals from the general
population[J]. J Am Coll Cardiol, 2010, 56(10):789-795.
[24] Kourliouros A, Camm AJ. Does inflammation influence
atrial fibrillation recurrence following catheter ablation?[J].
Europace, 2009, 11(2):135-137.
[25] Kocarnik JM, Pendergrass SA, Carty CL, et al. Multiancestral
analysis of inflammation-related genetic variants and
C-reactive protein in the population architecture using
genomics and epidemiology study[J]. Circ Cardiovasc Genet,
2014, 7(2):178-188.
[26] Psychari SN, Apostolou TS, Sinos L, et al. Relation of elevated
C-reactive protein and interleukin-6 levels to left atrial size
and duration of episodes in patients with atrial fibrillation[J].
Am J Cardiol, 2005, 95(6):764-767.
[27] Groenveld HF, Januzzi JL, Damman K, et al. Anemia and
mortality in heart failure patients a systematic review and
meta-analysis[J]. J Am Coll Cardiol, 2008, 52(10):818-827.
[28] Kim M, Hong M, Kim JY, et al. Clinical relationship between
anemia and atrial fibrillation recurrence after catheter ablation
without genetic background[J]. Int J Cardiol Heart Vasc, 2020,
27:100507.
[29] Dabbah S, Hammerman H, Markiewicz W, et al. Relation
between red cell distribution width and clinical outcomes
after acute myocardial infarction[J]. Am J Cardiol, 2010,
105(3):312-317.
[30] Li H, Liu T, Xu G, et al. Red blood cell distribution width
and the recurrence of atrial fibrillation after ablation in
patients with paroxysmal non-valvular symptomatic atrial
fibrillation[J]. Int J Cardiol, 2016, 203:834-836.
[31] Yucel H, Kaya H, Zorlu A, et al. Cancer antigen 125
concentrations and increased risk of new-onset atrial
fibrillation[J]. Herz, 2015, 40(Suppl 2):119-124.
[32] Huang Z, Liang X, Wang W, et al. Relationship between
plasma cancer antigen (CA)-125 level and one-year recurrence
of atrial fibrillation after catheter ablation[J]. Clin Chim Acta,
2020, 502:201-206.
[33] Njoku A, Kannabhiran M, Arora R, et al. Left atrial volume
predicts atrial fibrillation recurrence after radiofrequency
ablation: a meta-analysis[J]. Europace, 2018, 20(1):33-42.
[34] Chew DS, Black-Maier E, Loring Z, et al. Diagnosis-toablation
time and recurrence of atrial fibrillation following
catheter ablation: a systematic review and meta-analysis of
observational studies[J]. Circ Arrhythm Electrophysiol, 2020,
13(4):e008128.
备注/Memo
- 备注/Memo:
-
基金项目：国家自然科学基金（82000426）；山西省自然科学基金
（201801D121222）
通信作者：王睿， E-mail：wangruixnk@163.com
常用功能
统计/Statistics
- 摘要浏览/Viewed1
- 全文下载/Downloads239
- 评论/Comments
